Fuda Cancer Hospital
Liver cancer stage 2 treatment cost in China typically involves diagnostic imaging like a CT of the chest, which ranges from $300 to $600. Primary treatment options like chemotherapy for breast cancer cost $14,800 to $31,000, while radiation therapy for colorectal cancer runs from $11,500 to $27,500. Total expenses depend on the surgical approach and hospital tier, offering 50-70% savings compared to the US. Top treatment hubs include Beijing, Shanghai, and Guangzhou.
Typical Liver Cancer Stage 2 Treatment Costs in China
Bookimed Expert Insight: Patients seeking advanced alternatives to traditional chemotherapy should consider specialized centers in Guangzhou. Fuda Cancer Hospital is a JCI-accredited facility offering unique minimally invasive technologies like NanoKnife and cryosurgery. This clinic has treated over 30,000 international patients, specializing in late-stage success. For those requiring integrated care, experts like Liuying provide specialized expertise in thermal ablation for liver tumors.
| China | Turkey | Austria | |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Liver cancer stage 2 treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Liver cancer stage 2 treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Liver cancer stage 2 treatment journey.
Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.
Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.
Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
The doctor is a renowned expert in minimally invasive cryosurgery for cancer, serving as President and chief surgeon at Fuda Cancer Hospital since 2001. With a focus on oncology and minimally invasive procedures, the doctor has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures, treating patients aged 4 to 94.
Graduating from The Fourth Military Medical University with a specialty in thoracic and cardiac surgery, the doctor has contributed significantly to the field with over 100 published papers. Recognized with awards for outstanding contributions to cryosurgery, the doctor holds vice-presidential roles in both the Asian and International Societies of Cryosurgery.
The China Liver Cancer (CNLC) system defines Stage 2 as an intermediate level of liver cancer. It requires preserved liver function (Child-Pugh A or B). The disease must remain localized to the liver. There is no spread to major vessels, lymph nodes, or distant organs.
Bookimed Expert Insight: Chinese oncology centers often prioritize clinical resectability over traditional TNM staging labels. For example, Dr. Liuying at Jinshazhou Hospital manages cases where liver function impacts the plan more than tumor size. Fuda Cancer Hospital successfully treats Stage 2 cases using minimally invasive cryosurgery. This approach helps patients who cannot tolerate standard chemotherapy or major resection.
Patient Consensus: Patients note that staging labels in China may shift after surgery or biopsy. They emphasize confirming if the cancer is resectable or requires alternative therapies like TACE.
Surgery is a primary curative option for Stage 2 liver cancer in China. National guidelines prioritize surgical resection or transplantation for localized tumors. Chinese specialists use the China Liver Cancer staging system to determine operability. Success depends on liver function and tumor location after thorough scans.
Bookimed Expert Insight: Chinese oncology centers often apply a more aggressive surgical criteria than Western hospitals. Some facilities specialize in treating late-stage cancer for over 30,000 international patients. These centers regularly combine resection with specialized technologies like vascular interventional therapy. This approach allows surgeons to operate on tumors previously considered too risky or inoperable.
Patient Consensus: Patients note that liver health often matters more than the stage label itself. Many emphasize that a hepatobiliary surgeon’s expert opinion is vital before deciding against surgery.
China combines immunotherapy with localized treatments by integrating checkpoint inhibitors with procedures like TACE, cryosurgery, or NanoKnife. This multi-modal strategy turns immune-reactive tumors into hot ones to increase response rates. Centers frequently use hepatic artery infusion and ablation to trigger systemic anti-tumor responses through antigen release.
Bookimed Expert Insight: A distinct pattern in China is the aggressive use of downstaging strategies for stage 2 liver cancer. Clinics like Fuda Cancer Hospital utilize JCI-accredited facilities to combine specialized vascular interventional therapy with immunotherapy. This sequence aims to shrink lesions enough for curative surgery rather than relying purely on systemic drugs. Specialists like Dr. Liuying focus on microwave ablation to reduce tumor burden before starting immunotherapy cycles.
Patient Consensus: Patients note that doctors prioritize stabilizing liver function before starting these intense combinations. They also emphasize that the sequence of local treatment followed by immunotherapy helps manage side effects better.
Traditional Chinese Medicine cannot cure Stage 2 liver cancer on its own. Modern interventions like surgical resection or ablation are required to remove tumors. Chinese oncology centers typically use integrative care. They combine Western surgery with herbal formulas to manage side effects.
Bookimed Expert Insight: High-volume centers like Fuda Cancer Hospital demonstrate that successful outcomes rely on multi-modality approaches. They utilize NanoKnife and cryosurgery alongside supportive therapies for over 30,000 international patients. Choosing a clinic with JCI accreditation ensures that these integrative methods meet strict global safety standards. This is vital because incorrect herbal dosages can cause liver toxicity.
Patient Consensus: Patients note that feeling better from herbs does not always mean the tumor is shrinking. They emphasize tracking progress through CT scans or MRI rather than just physical comfort.